Want to see MLSS full AI Analyst Report?

Milestone Scientific (MLSS) Price & Analysis

289 Followers

MLSS Stock Chart & Stats

$0.29

$0.17(16.41%)

At close: Jan 08 4:00 PM EST

$0.29

$0.17(16.41%)

Day’s Range― - ―

52-Week Range$0.22 - $0.68

Previous CloseN/A

Volume1.27M

Average Volume (3M)172.66K

Market Cap

$33.78M

Enterprise Value$29.73M

Total Cash (Recent Filing)$1.19M

Total Debt (Recent Filing)$985.35K

Price to Earnings (P/E)―

Beta0.83

Next Earnings

Aug 18, 2026

EPS Estimate

-0.01

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.06

Shares Outstanding88,449,410

10 Day Avg. Volume233,274

30 Day Avg. Volume172,658

Financial Highlights & Ratios

PEG Ratio-0.21

Price to Book (P/B)7.97

Price to Sales (P/S)2.50

P/FCF Ratio-7.64

Enterprise Value/Market Cap0.88

Enterprise Value/Revenue3.34

Enterprise Value/Gross Profit4.74

Enterprise Value/Ebitda-6.85

Forecast

1Y Price Target

$1.00

Price Target Upside244.83% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering1

EPS Forecast (FY)-0.04

Revenue Forecast (FY)$9.86M

Bulls Say, Bears Say

Bulls Say

High Gross MarginA sustained gross margin above 70% indicates strong unit economics and pricing power for Milestone's products. High product-level profitability provides durable upside to operating leverage as revenues scale, helping the company reach cash-flow breakeven without relying solely on cost cuts.

Material Operating Expense CutsManagement’s >30% opex reduction materially narrowed losses (~58% improvement in operating/net loss), showing execution on cost structure. Structural expense discipline extends runway and improves the likelihood of reaching cash-flow breakeven in early 2027 if revenue growth continues.

Completed Financing And Modest LeverageThe $2.15M PIPE plus modest historical leverage (debt/equity ~0.43) meaningfully eases near-term liquidity pressure. Added capital funds sales, inventory and marketing investments that can sustainably support commercial expansion without immediate high-cost debt.

Bears Say

Negative Operating And Free Cash FlowPersistent negative operating and free cash flow force repeated financings and constrain strategic optionality. Until operating cash turns positive, the company must divert management attention to funding rather than growth, increasing execution risk and dilution over the medium term.

Declining Revenue TrendA nearly 25% TTM revenue decline undermines operating leverage and makes fixed costs harder to absorb. Although CompuFlo medical revenue doubled to only about $108k in Q1, its small absolute base limits near-term revenue diversification and keeps top-line recovery uncertain.

Dependence On Medicare/MAC ReimbursementCommercial scale for the medical segment hinges on reimbursement classification and MAC engagement. Delays or unfavorable classification slow clinician adoption and utilization increases, creating a multi‑month timing risk that can materially delay nonlinear revenue expansion.

Milestone Scientific News

Midday Fly By: Nike reports on turnaround progress, Kroger buying Giant Eagle

The major averages were mixed near noon as investors weigh renewed uncertainty in the Middle East against continued...

13d ago

Milestone Scientific reports preliminary Q2 revenue $2.8M, two estimates $2.5M

Revenue was driven by base business performance contributing approximately $2.4M, which was bolstered by approximately $500,000 in upside...

13d ago

MLSS

Milestone Scientific Restructures Leadership and Governance Agreements

Milestone Scientific ( ($MLSS) ) just unveiled an announcement. On June 19, 2026, Milestone Scientific restructured its long-standing...

19d ago

MLSS

Milestone Scientific registers to sell 7.96M shares of common stock for holders

This filing relates to the offer and sale from time to time by the selling stockholder of up...

1M ago

MLSS

Milestone Scientific Earnings Call Signals Cautious Upswing

Milestone Scientific Inc (($MLSS)) has held its Q1 earnings call. Read on for the main highlights of the...

2M ago

MLSS

Midday Fly By: Cisco reports Q3 beat, Chinese firms cleared to buy Nvidia chips

The major averages were sharply higher near noon amid renewed optimism around the talks between U.S. President Trump...

2M ago

AEM

FNV

Milestone Scientific reports Q1 EPS (1c), consensus (1c)

Reports Q1 revenue $2.16M, consensus $2.5M. “Our first quarter results reflect continued progress as we execute on the...

2M ago

MLSS

Milestone Scientific backs FY26 revenue view $9.8M-$10.2M, consensus $9.91M

The company said, “Management reaffirms its outlook for the year ending December 31, 2026, with expected revenue of...

2M ago

MLSS

Milestone Scientific Restructures Executive Equity Incentive Programs

Milestone Scientific ( ($MLSS) ) has shared an announcement. On April 30, 2026, Milestone Scientific’s compensation committee approved...

2M ago

MLSS

Milestone Scientific Completes Private Placement to Strengthen Finances

An update from Milestone Scientific ( ($MLSS) ) is now available. On April 20, 2026, Milestone Scientific Inc....

3M ago

MLSS

Milestone Scientific Outlines High-Risk Turnaround in Earnings

Milestone Scientific Inc (($MLSS)) has held its Q4 earnings call. Read on for the main highlights of the...

3M ago

MLSS

Milestone Scientific Amends Agreement to Enhance Financing Flexibility

The latest update is out from Milestone Scientific ( ($MLSS) ). On March 31, 2026, Milestone Scientific Inc....

3M ago

MLSS

Milestone Scientific reports Q4 revenue $2.1M, consensus $2.31M

Eric Hines, CEO of Milestone Scientific (MLSS) commented: “When I joined Milestone in August 2025, we were in...

3M ago

MLSS

Milestone Scientific sees FY26 revenue $9.8M-$10.2M, consensus $9.91M

The company said, “As we enter 2026, we expect to transition from a period of stabilization to a...

3M ago

MLSS

MLSS FAQ

What was Milestone Scientific’s price range in the past 12 months?

Milestone Scientific lowest stock price was $0.22 and its highest was $0.68 in the past 12 months.

What is Milestone Scientific’s market cap?

Milestone Scientific’s market cap is $33.78M.

When is Milestone Scientific’s upcoming earnings report date?

Milestone Scientific’s upcoming earnings report date is Aug 18, 2026 which is in 35 days.

How were Milestone Scientific’s earnings last quarter?

Milestone Scientific released its earnings results on May 14, 2026. The company reported -$0.01 earnings per share for the quarter, missing the consensus estimate of N/A by N/A.

Is Milestone Scientific overvalued?

According to Wall Street analysts Milestone Scientific’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Milestone Scientific pay dividends?

Milestone Scientific does not currently pay dividends.

What is Milestone Scientific’s EPS estimate?

Milestone Scientific’s EPS estimate is -0.01.

How many shares outstanding does Milestone Scientific have?

Milestone Scientific has 88,449,410 shares outstanding.

What happened to Milestone Scientific’s price movement after its last earnings report?

Milestone Scientific reported an EPS of -$0.01 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -4.286%.

Which hedge fund is a major shareholder of Milestone Scientific?

Currently, no hedge funds are holding shares in MLSS

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Milestone Scientific Stock Smart Score

Underperform

Analyst Consensus

Moderate Buy

Average Price Target:
$1.00 (244.83% Upside)

Technicals

Fundamentals

Return on Equity

-166.28%

Trailing 12-Months

Asset Growth

-12.38%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Milestone Scientific

Milestone Scientific Inc. is dedicated to the innovation, refinement, and global distribution of advanced diagnostic and therapeutic injection technologies and devices. These solutions cater to the medical, dental, and cosmetic industries, with a presence in the United States, China, and other international markets. The company's operations are divided into two main segments: Dental and Medical. Within its Dental division, key products include CompuDent and the STA Single Tooth Anesthesia System, both instrumental for delivering local anesthetics across all dental procedures. For broader applications, the firm offers CompuFlo, a sophisticated computer-controlled system capable of delivering drugs, anesthetics, and other medicaments comfortably and precisely, as well as aspirating bodily fluids or prior injections. Complementing this, a disposable injection handpiece provides precise tactile control during administration. In the Medical segment, Milestone Scientific introduces the CompuFlo Epidural, a computer-guided anesthesia system designed for a variety of medical applications. Additionally, their CompuMed system is utilized in numerous specialized procedures, including plastic surgery, hair restoration, colorectal surgery, podiatry, dermatology, and orthopedics, among others. Headquartered in Livingston, New Jersey, Milestone Scientific Inc. was established in 1989.

Milestone Scientific (MLSS) Earnings & Revenues

Historic Earnings Reports

MLSS Stock 12 Month Forecast

Average Price Target

$1.00

▲(244.83% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"2":"$2","-1":"-$1","-0.25":"-$0.25","0.5":"$0.5","1.25":"$1.25"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":1,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$1.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":1,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$1.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":1,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$1.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[-1,-0.25,0.5,1.25,2],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Oct<br/>2025","6":"Jan<br/>2026","9":"Apr<br/>2026","12":"Jul<br/>2026","25":"Jul<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.35,0.39999999999999997,0.44999999999999996,0.5,0.55,0.6,0.65,0.7,0.75,0.8,0.85,0.9,0.9500000000000001,{"y":1,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.35,0.39999999999999997,0.44999999999999996,0.5,0.55,0.6,0.65,0.7,0.75,0.8,0.85,0.9,0.9500000000000001,{"y":1,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.35,0.39999999999999997,0.44999999999999996,0.5,0.55,0.6,0.65,0.7,0.75,0.8,0.85,0.9,0.9500000000000001,{"y":1,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":0.638,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.43,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.598,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.45,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.419,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.301,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.273,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.267,"date":1769904000000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":0.253,"date":1772323200000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":0.298,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.338,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.385,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.35,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >